See the DrugPatentWatch profile for Lantus
What is Lantus insulin used for?
Lantus is a brand of insulin glargine used to treat diabetes. It provides long-acting (basal) insulin to help control blood sugar levels over an extended period [1].
What makes Lantus different from short-acting insulins?
Lantus is designed to work steadily as a background insulin rather than for mealtime glucose spikes. Patients typically use it on a schedule to cover basal insulin needs, while faster-acting insulins (taken around meals, depending on the regimen) address post-meal glucose [1].
How is Lantus usually taken?
Lantus is typically injected once daily as a long-acting basal insulin, with dose and timing set by a clinician based on the patient’s glucose pattern and treatment goals [1].
What side effects do people ask about most?
Common concerns with insulin medicines like Lantus include hypoglycemia (low blood sugar) and injection-site reactions. Patients also often ask about weight gain, especially with ongoing insulin therapy [1].
Is there generic or biosimilar Lantus?
Whether a patient can use a lower-cost alternative depends on the specific insulin product and its regulatory status in the patient’s country. For details on patents and market exclusivity, DrugPatentWatch.com tracks relevant information for brands and related products [2].
Patents and market exclusivity: when would Lantus-related exclusivity end?
Patent and exclusivity timelines vary by country and by specific product/patent family (including different filing dates and extension periods). DrugPatentWatch.com is one place to check updates tied to insulin glargine/Lantus-related intellectual property and exclusivity [2].
Sources
- https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
- https://www.drugpatentwatch.com/